Latest Oncology News

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer

December 10th 2025

Kyle Doherty

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer

December 10th 2025

Silas Inman

The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer

December 10th 2025

Roman Fabbricatore

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer

December 10th 2025

Andrea Eleazar, MHS

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis

December 10th 2025

Kyle Doherty

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Latest Oncology Videos

Dr Tolaney on the Design of the ELEGANT Trial in ER+, HER2-Negative Early Breast Cancer

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Tolaney on Implications of Data for Sacituzumab Govitecan in First-line Advanced TNBC

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML

Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer

Understanding CA-LEMS Pathophysiology

Clinical Presentation and Early Identification of Cancer-Associated LEMS

Ongoing Research in Primary CNS Malignancies

The FORTE Trial: Data for Plixorafenib in BRAF V600+ CNS Tumors

Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL

Decoding Developments in GVHD Management With Drs Salhotra and Negrin

Dr Vincent-Salomon on Persisting Gaps in Clinical Interpretation of Invasive Lobular Carcinoma

Exploring Percutaneous Hepatic Perfusion in Metastatic Uveal Melanoma

Current Treatment Standards in Metastatic Uveal Melanoma

Inadequate Response and Second-Line Treatment of NETS

Site of Origin and Treatment of NETS

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma

Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML

Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla

Reflecting on Research Highlights in Acute Leukemia and Multiple Myeloma With Drs Hildebrandt and Baljevic

Dr Freedland on the Next Steps for Evaluating Enzalutamide in Prostate Cancer

All Oncology News

Orca-Q Yields Low Rates of GVHD and Non-Relapse Mortality in High-Risk Hematologic Malignancies

December 10th 2025

Chris Ryan

Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.

International Breast Cancer Conference Features UCSF Experts

December 10th 2025

UCSF Health

Breast cancer experts from UCSF Health will present trial results and clinical guidance at the annual San Antonio Breast Cancer Symposium.

Axi-Cel Is Safe and Effective in Real-World R/R Follicular Lymphoma

December 10th 2025

Alex Biese

Axi-cel led to durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Pelabresib Plus Ruxolitinib Bests Ruxolitinib Monotherapy in JAK Inhibitor-Naive Myelofibrosis

December 9th 2025

Paige Britt

Pelabresib plus ruxolitinib improved primary and secondary efficacy end points vs ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Axatilimab Shows Long-Term Safety and Clinical Benefit in Pretreated Chronic GVHD

December 9th 2025

Jonah Feldman

Long-term follow-up data from the AGAVE-201 trial showed that safety and survival outcomes with axatilimab were maintained in patients with chronic GVHD.

Early Data Show Deep MRD-Negative Responses, CAR T-Cell Persistence With KLN-1010 in R/R Myeloma

December 9th 2025

Courtney Flaherty

The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.

BCMA/CD19-Directed CAR T-Cell Therapy Yields 100% ORR in Newly Diagnosed Myeloma

December 9th 2025

Chris Ryan

GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.

Limited-Duration Teclistamab Drives Durable Responses in Relapsed/Refractory Myeloma

December 9th 2025

Caroline Seymour

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

Teclistamab Plus Daratumumab Yields OS, PFS Benefit in R/R Multiple Myeloma

December 9th 2025

Jason Broderick

Teclistamab/daratumumab improved survival outcomes and led to deep MRD-negative responses vs daratumumab-based regimens in relapsed/refractory myeloma.

Pirtobrutinib Yields Improved Efficacy Over BR in First-Line CLL/SLL

December 9th 2025

Sabrina Serani

Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.

Zanubrutinib Plus Venetoclax Displays Long-Term PFS Benefit in Untreated CLL/SLL

December 9th 2025

Tony Berberabe, MPH

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

FDA Approves Omidubicel for Adult and Pediatric Patients With Severe Aplastic Anemia

December 9th 2025

Courtney Flaherty

The FDA has approved the HSCT therapy for patients 6 years or older with SAA following reduced-intensity conditioning who do not have a compatible donor.

GLPG5101 Produces Responses With Manageable Safety in R/R NHL, MCL

December 9th 2025

Paige Britt

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

MK-1045 Therapy Proves Active, Safe With Dose Modification in Relapsed/Refractory ALL

December 9th 2025

Roman Fabbricatore

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL

December 9th 2025

Kristi Rosa

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

See All News